Drug Profile
Research programme: triamcinolone ophthalmic - OphthalmoPharma
Latest Information Update: 05 Nov 2021
Price :
$50
*
At a glance
- Originator OphthalmoPharma
- Class Analgesics; Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Age-related macular degeneration
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Switzerland (Ophthalmic)
- 18 Jul 2006 Preclinical trials in Age-related macular degeneration in Switzerland (Ophthalmic)